108 related articles for article (PubMed ID: 12679736)
1. Immunohistochemical expression of receptor-tyrosine kinase c-kit protein in invasive ductal carcinoma of the pancreas.
Nio Y; Omori H; Toga T; Hashimoto K; Itakura M; Koike M; Yano S; Higami T
Anticancer Drugs; 2003 Apr; 14(4):313-9. PubMed ID: 12679736
[TBL] [Abstract][Full Text] [Related]
2. Immunohistochemical expression of receptor-tyrosine kinase c-kit protein and TGF-beta1 in invasive ductal carcinoma of the pancreas.
Nio Y; Omori H; Hashimoto K; Itakura M; Koike M; Yano S; Toga T; Higami T; Maruyama R
Anticancer Res; 2005; 25(5):3523-9. PubMed ID: 16101174
[TBL] [Abstract][Full Text] [Related]
3. Apoptosis and expression of Bcl-2 and Bax proteins in invasive ductal carcinoma of the pancreas.
Nio Y; Iguchi C; Yamasawa K; Sasaki S; Takamura M; Toga T; Dong M; Itakura M; Tamura K
Pancreas; 2001 Apr; 22(3):230-9. PubMed ID: 11291923
[TBL] [Abstract][Full Text] [Related]
4. Analysis of c-kit protein expression in pancreatic neoplasms and its implication for prognosis.
Kimura W; Ma J; Takeshita A; Yamamoto T; Moriya T; Hirai I; Fuse A
Hepatogastroenterology; 2007 Dec; 54(80):2203-8. PubMed ID: 18265633
[TBL] [Abstract][Full Text] [Related]
5. Clinicopathological significance of abnormalities in Gadd45 expression and its relationship to p53 in human pancreatic cancer.
Yamasawa K; Nio Y; Dong M; Yamaguchi K; Itakura M
Clin Cancer Res; 2002 Aug; 8(8):2563-9. PubMed ID: 12171884
[TBL] [Abstract][Full Text] [Related]
6. Implication of thymidylate synthase in the outcome of patients with invasive ductal carcinoma of the pancreas and efficacy of adjuvant chemotherapy using 5-fluorouracil or its derivatives.
Takamura M; Nio Y; Yamasawa K; Dong M; Yamaguchi K; Itakura M
Anticancer Drugs; 2002 Jan; 13(1):75-85. PubMed ID: 11914644
[TBL] [Abstract][Full Text] [Related]
7. Expression of Bcl-2 and p53 protein in resectable invasive ductal carcinoma of the pancreas: effects on clinical outcome and efficacy of adjuvant chemotherapy.
Nio Y; Dong M; Iguchi C; Yamasawa K; Toga T; Itakura M; Tamura K
J Surg Oncol; 2001 Mar; 76(3):188-96. PubMed ID: 11276023
[TBL] [Abstract][Full Text] [Related]
8. Immunohistochemical analysis of platelet-derived growth factor receptor-alpha, -beta, c-kit, c-abl, and arg proteins in glioblastoma: possible implications for patient selection for imatinib mesylate therapy.
Haberler C; Gelpi E; Marosi C; Rössler K; Birner P; Budka H; Hainfellner JA
J Neurooncol; 2006 Jan; 76(2):105-9. PubMed ID: 16205964
[TBL] [Abstract][Full Text] [Related]
9. Identification and treatment of chemoresistant inoperable or metastatic GIST: experience with the selective tyrosine kinase inhibitor imatinib mesylate (STI571).
Demetri GD
Eur J Cancer; 2002 Sep; 38 Suppl 5():S52-9. PubMed ID: 12528773
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of imatinib mesylate (Gleevec) and immunohistochemical expression of c-Kit and PDGFR-beta in a Gynecologic Oncology Group Phase Il Trial in women with recurrent or persistent carcinosarcomas of the uterus.
Huh WK; Sill MW; Darcy KM; Elias KM; Hoffman JS; Boggess JF; Alvarez RD; Long HJ; O'Malley DM; Birrer MJ
Gynecol Oncol; 2010 May; 117(2):248-54. PubMed ID: 20189232
[TBL] [Abstract][Full Text] [Related]
11. C-kit expression in human osteosarcoma and in vitro assays.
Miiji LN; Petrilli AS; Di Cesare S; Odashiro AN; Burnier MN; de Toledo SR; Garcia RJ; Alves MT
Int J Clin Exp Pathol; 2011; 4(8):775-81. PubMed ID: 22135725
[TBL] [Abstract][Full Text] [Related]
12. The dissociated expression of protein and messenger RNA of DPC4 in human invasive ductal carcinoma of the pancreas and their implication for patient outcome.
Toga T; Nio Y; Hashimoto K; Higami T; Maruyama R
Anticancer Res; 2004; 24(2C):1173-8. PubMed ID: 15154643
[TBL] [Abstract][Full Text] [Related]
13. The stem cell factor-c-kit system and mast cells in human pancreatic cancer.
Esposito I; Kleeff J; Bischoff SC; Fischer L; Collecchi P; Iorio M; Bevilacqua G; Büchler MW; Friess H
Lab Invest; 2002 Nov; 82(11):1481-92. PubMed ID: 12429808
[TBL] [Abstract][Full Text] [Related]
14. Comparative significance of p53 and WAF/1-p21 expression on the efficacy of adjuvant chemotherapy for resectable invasive ductal carcinoma of the pancreas.
Nio Y; Dong M; Uegaki K; Hirahara N; Minari Y; Sasaki S; Takamura M; Iguchi C; Tamura K
Pancreas; 1999 Mar; 18(2):117-26. PubMed ID: 10090408
[TBL] [Abstract][Full Text] [Related]
15. Expression of retinoblastoma and p53 pathway-related proteins in resectable invasive ductal carcinoma of the pancreas: potential cooperative effects on clinical outcome.
Hashimoto K; Nio Y; Koike M; Itakura M; Yano S; Higami T; Maruyama R
Anticancer Res; 2005; 25(2B):1361-8. PubMed ID: 15865092
[TBL] [Abstract][Full Text] [Related]
16. The stem cell factor/c-kit receptor pathway enhances proliferation and invasion of pancreatic cancer cells.
Yasuda A; Sawai H; Takahashi H; Ochi N; Matsuo Y; Funahashi H; Sato M; Okada Y; Takeyama H; Manabe T
Mol Cancer; 2006 Oct; 5():46. PubMed ID: 17044945
[TBL] [Abstract][Full Text] [Related]
17. The tyrosine kinase inhibitor imatinib fails to inhibit pancreatic cancer progression.
Chen J; Röcken C; Nitsche B; Hosius C; Gschaidmeier H; Kahl S; Malfertheiner P; Ebert MP
Cancer Lett; 2006 Feb; 233(2):328-37. PubMed ID: 15893416
[TBL] [Abstract][Full Text] [Related]
18. Expression of Kit and platelet-derived growth factor receptors alpha and beta in cholangiocarcinoma, and case report of therapy with imatinib mesylate (STI571).
Holcombe RF; Gu M; Imagawa D; Milovanovic T
Anticancer Drugs; 2003 Sep; 14(8):651-7. PubMed ID: 14501388
[TBL] [Abstract][Full Text] [Related]
19. Treatment of patients with advanced gastrointestinal stromal tumor of small bowel: implications of imatinib mesylate.
Yeh CN; Chen TW; Wu TJ; Hsueh S; Jan YY
World J Gastroenterol; 2006 Jun; 12(23):3760-5. PubMed ID: 16773696
[TBL] [Abstract][Full Text] [Related]
20. Heterogeneic distribution of thymidine phosphorylase between primary tumors and metastatic lesions of human pancreatic ductal carcinoma: implications for the efficacy of chemotherapy with 5-FU or its derivatives.
Minari Y; Nio Y; Hirahara N; Dong M
Cancer Chemother Pharmacol; 2001 May; 47(5):415-22. PubMed ID: 11391857
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
